News Article
QMC’s quantum dots to give Nanoaxis a helping hand
The firms are uniting to develop tetrapod quantum dots including cadmium selenide based ones to produce cancer diagnostic kits and tools to diagnose or treat diseases such as Alzheimer's, diabetes, breast cancer and major depression.
Quantum Materials Corporation (QMC) and Nanoaxis, have formed a technology alliance combining QMC’s tetrapod quantum dot mass production technology with NanoAxis’ advanced research expertise and intellectual property in gene therapy biomedical nanotechnology.
The aim of the alliance is to develop tetrapod quantum dot based cancer diagnostic kits and for other tools used in theranostic applications including Alzheimer's, type 1 and type 2 diabetes, breast cancer and major depression.
QMC will develop specialised quantum dots for NanoAxis to use alongside its proprietary biomedical nanomaterials for a multiplexing drug delivery platform for drug/gene therapy and diagnostic medical devices technologies. The technology alliance will allow these technologies to be developed rapidly due to Quantum Materials' ability to create the highest quality quantum dots in quantities necessary to support multiple projects with timely deliveries.
The immediate goal is to develop a QD microarray device for detection, diagnosis and quantification of early cancers. The QD-MI device will be designed for rapid detection and grading of various multiple cancers using blood assays with higher accuracy and at less cost than current single ELISA assays. All diagnostic and pharmaceutical products will include QMC quantum dots functionalised by NanoAxis biomedical IP nanotechnology.
According to a recent report published by BCC Research the total market for nanobiotechnology products is $19.3 billion in 2010 and is growing at a compound annual growth rate of 9% to reach a forecast market size of $29.7 billion by 2015.
Stephen Squires, CEO and President of Quantum Material Corporation and its subsidiary Solterra Renewable Resources, commented, "This alliance will foster a breakthrough in theranostic science as it enables mass production of NanoAxis nanomedicine product pipeline. The goal is to make these biologically adapted quantum dots the ideal choice for in vitro and in vivo applications for high throughput, efficient and cost effective applications in the biological and medical market spaces. Quantum Materials' ability to create tetrapod quantum dots of various materials, shapes, sizes and characteristics that can serve as delivery platforms for Nanoaxis products will allow for rapid commercial development."
"This is an exciting moment for our industry. We see this Technology Alliance between NanoAxis and Quantum Materials Corp as bringing industrial scale production to the cutting edge of nanomedicine research. The synergy of the combined technologies is enhanced by the cooperation of our two companies' seasoned management and research teams and we believe this partnership will be the catalyst of many biomedicine advances", said Krishnan Chakravarthy, NanoAxis LLC President and CEO.
Siddhartha Kamisetti, Director of Global Strategy at NanoAxis, added, "This alliance opens the door for pioneering developments in the biomedical space and presents a significant opportunity to assist people suffering from a host of diseases and ailments throughout the world."
